NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/04/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization425.62 mln
Float28.06 mln
Earnings Date05/19/2026
Piotroski F-Score
3
/ 9
Below average
1-Year Forecast
16.25
Transformational upside
Relative Strength
89
/ 100
Strongly outperforming
Debt / Equity
0.00
Debt-free
ROE
-32.23
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Climb Bio Inc. is a clinical-stage biotechnology company based in Wellesley Hills, Massachusetts, dedicated to creating treatments for patients with immune-related diseases. Its primary drug candidate, budoprutug, is an antibody that targets B-cell driven conditions and is currently being tested in Phase 2 trials for membranous nephropathy and immune thrombocytopenia, as well as in a Phase 1b trial for lupus. The company is also advancing an early-stage antibody called CLYM116, aimed at treating IgA nephropathy and similar conditions. Formerly known as Eliem Therapeutics Inc., the company adopted its current name in October 2024.
